Memantine Vipharm (Memantine Hydrochloride)

• Memantine is indicated for the treatment of Alzheimer’s disease, targeting the glutamatergic pathway to improve cognition.
• Alzheimer’s disease: helps to stabilize or modestly improve cognitive function and daily living activities in patients with mild to moderate disease.

• Memantine acts as a non‑competitive antagonist at the N‑methyl‑D‑aspartate (NMDA) receptor. By binding to the receptor‑associated ion channel with moderate affinity, it blocks excessive calcium influx caused by prolonged glutamate activation, thereby reducing excitotoxic neuronal injury while preserving normal synaptic transmission essential for learning and memory. The drug’s voltage‑dependent blocking properties allow it to disengage during normal physiological activity, minimizing interference with normal neurotransmission and providing a neuroprotective effect over chronic treatment.

Memantine may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness that may affect balance.
• Headache: mild to moderate pain in the head, sometimes accompanied by tension.
• Constipation: reduced bowel movements or hard stools, potentially causing abdominal discomfort.
• Fatigue: feeling unusually tired or weak, which can interfere with daily activities.

Serious or Rare Side Effects

• Seizures: convulsive episodes that may require emergency medical attention.
• Severe allergic reaction: rash, swelling, or difficulty breathing indicating possible anaphylaxis.
• Hepatic dysfunction: elevated liver enzymes, jaundice, or other signs of liver injury.

When prescribing Memantine, clinicians should consider several safety precautions to minimize risks.

• Renal function: assess kidney function before initiation and monitor periodically.
• Hepatic function: evaluate liver status, especially in patients with pre‑existing liver disease.
• Concomitant NMDA antagonists: avoid using with other NMDA‑blocking agents to prevent additive neuro‑inhibition.
• History of seizures: use cautiously in patients with seizure disorders and monitor closely.
• Pregnancy and lactation: safety not established; weigh potential benefits against unknown risks.
• Store at room temperature: keep below 25 °C in the original container, protect from moisture and light.

Memantine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Other NMDA antagonists (e.g., amantadine, ketamine): may increase neuro‑inhibitory effects.
• Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): can reduce memantine plasma concentrations.
• High‑dose zinc supplements: may interfere with absorption and reduce effectiveness.

Moderate Interactions (Monitor Closely)

• CNS depressants (e.g., benzodiazepines, opioids): may enhance sedation or dizziness.
• Anticholinergic agents (e.g., diphenhydramine): may worsen cognitive side effects.